What is detectable PSA post prostectomy and post radiation
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive summary of detectable PSA after prostatectomy and radiation therapy, drawn from authoritative urology and medicine textbooks.
PSA After Radical Prostatectomy
Expected Response
After complete surgical removal of all prostate tissue, PSA should become undetectable within 6 weeks. Because no prostate tissue remains, there should be zero measurable PSA in a successfully treated patient. — Harrison's Principles of Internal Medicine 22E
Biochemical Recurrence — Definition
The AUA-recommended standard definition (adopted also by European guidelines) is:
PSA ≥ 0.2 ng/mL confirmed on a second measurement
This threshold was chosen to:
- Serve as an early marker of treatment failure before clinical progression
- Be low enough to allow candidates for early salvage therapy
- Enable comparisons across patient series
The Memorial Sloan Kettering analysis of 3,125 patients found that PSA ≥ 0.4 ng/mL with subsequent increase was the best predictor of metastatic progression — but 0.2 ng/mL is the accepted intervention threshold. — Campbell-Walsh-Wein Urology
What Detectable PSA Means
Approximately 25–41% of men develop PSA recurrence by 10 years post-surgery; in high-risk prostate cancer, the rate can reach 60% at 5 years.
Not all detectable PSA indicates clinical progression. Possible explanations include:
- Residual benign prostatic tissue in the surgical bed
- PSA production at low levels by nonprostatic cells
- Residual low-grade, indolent cancer that may never cause harm
In one cohort of 622 intermediate/high-risk patients with detectable PSA, only 52% went on to clinical failure at a median of ~5–10 years.
Ultrasensitive PSA (uPSA)
Standard assays detect down to 0.1–0.2 ng/mL; ultrasensitive assays go to 0.001 ng/mL.
| uPSA Nadir Post-RP | 3-year Biochemical Recurrence-Free Survival |
|---|---|
| < 0.001 ng/mL | 95.5% |
| ≥ 0.05 ng/mL | 41.5% |
- A uPSA threshold of 0.01 ng/mL is clinically meaningful — values below this yield a median biochemical recurrence-free survival of 15.2 years vs. 10 years for those ≥ 0.01.
- For every month without detectable uPSA, the odds of high-risk recurrence decrease by 4%.
- In low-risk disease, detectable vs. undetectable uPSA makes little difference (91% vs. 89% recurrence-free survival), so ultrasensitive testing is most impactful in intermediate- and high-risk patients.
PSA After Radiation Therapy
Expected Response
Unlike surgery, radiation does not render PSA undetectable. Normal (non-malignant) prostate cells continue to produce PSA even if cancer cells are eliminated. The maximal PSA-lowering effect of radiation may take up to 2 years to manifest. — Harrison's; Goldman-Cecil Medicine
Biochemical Recurrence — "Phoenix" Definition
Established by a multidisciplinary panel meeting in Phoenix, Arizona (2006):
PSA nadir + 2 ng/mL (i.e., a rise of ≥ 2 ng/mL above the post-treatment nadir PSA)
The date of failure is called at the time of the PSA rise ("nadir + 2 at call"). This definition applies to patients who may also have received concurrent androgen deprivation therapy (ADT).
The Phoenix definition outperforms the older ASTRO definition in predicting metastatic disease, disease-specific mortality, and overall survival on multivariable analysis. — Campbell-Walsh-Wein Urology
Goldman-Cecil adds a parallel criterion: PSA doubling within 3 months also indicates recurrence.
PSA Bounce Phenomenon
A transient PSA rise post-radiation is well-recognized and must not be confused with recurrence:
- Defined as a rise of 0.1–0.5 ng/mL above the pre-bounce PSA followed by a return to baseline
- Occurs at a mean of ~9 months post-therapy
- Thought to result from post-treatment prostatitis or delayed cell death from sublethal radiation dose
- Paradoxically associated with improved biochemical recurrence-free survival
- Seen in ~35% of brachytherapy patients
Summary Table
| Parameter | Post-Prostatectomy | Post-Radiation |
|---|---|---|
| Normal post-treatment PSA | Undetectable (< 0.1 ng/mL) | Detectable (slow decline over months–years) |
| Biochemical recurrence threshold | ≥ 0.2 ng/mL (confirmed ×2) | Nadir + 2 ng/mL ("Phoenix" definition) |
| Time to recurrence detection | Weeks post-op | Up to 2 years for full effect |
| Common pitfall | Low-level detectable PSA (may be benign) | PSA bounce (transient rise, not failure) |
| PSA doubling time (PSADT) | Key prognostic factor | Key prognostic factor |
PSA doubling time is critical in both settings: PSADT ≥ 14 months signals low clinical risk; PSADT ≤ 3 months signals high risk for metastatic progression. — Harrison's Principles of Internal Medicine 22E
This is a shared conversation. Sign in to Orris to start your own chat.